CRISPR/Cas9-mediated reversibly immortalized mouse bone marrow stromal stem cells (BMSCs) retain multipotent features of mesenchymal stem cells (MSCs)

INTRODUCTION

Considered as multipotent progenitors, mesen-chymal stem cells (MSCs) are a heterogeneous population of non-hematopoietic progenitor cells that can undergo self-renewal and differentiate into multi-lineages [1-5]. MSCs were originally described by Friedentstein and colleagues near 50 years ago as adherent cells with a fibroblast-like appearance capable of differentiating into osteocytes, chondrocytes, adipocytes, tenocytes and myocytes upon appropriate stimulations [6, 7]. For instance, osteogenic differentiation of MSCs is a cascade that recapitulates most, if not all, of the molecular events occurring during embryonic skeletal development [8]. While many signaling pathways play important roles in regulating osteogenic differentiation [4, 9-17], bone morphogenetic proteins (BMPs) are considered as a group of the most potent osteoinductive factors [4, 18-20]. We previously demonstrated that BMP9 (also known as growth differentiation factor 2, or GDF2) is one of the most potent BMPs among the 14 types of BMPs in inducing osteogenic differentiation of MSCs [21-24].

MSCs have attracted significant attention for their potential role in elucidating differentiation pathways, promoting tissue engineering and functioning as immunomodulators in autoimmune diseases [3, 4]. While MSCs can be isolated from various tissues [2, 3, 25], MSCs isolated from the bone marrow, a subset of bone marrow stromal cells, are the most characterized [1, 5]. Nonetheless, clinical translation of MSCs is hampered by many issues. One of the major technical challenges is to obtain adequate number of therapeutic cells, which requires expansion of MSCs while maintaining their stem cell phenotype in vitro. Even though BMSCs are one of the most commonly-used MSCs, their isolation and maintenance is time-consuming and labor-intensive. Thus, immortalized bone marrow stromal stem cells (BMSCs) can be a promising alternative cell source of primary MSCs for basic and pre-clinical studies.

One commonly-used strategy is to express an immortalizing oncogene in primary cells, which is exemplified by the use of simian virus SV40 large T antigen (SV40T) [26]. SV40T is a multifunctional regulatory protein which binds and inactivates p53 and Rb, at least in part leading to unlimited life span [26, 27]. Unlike most other oncogene products and owing to its multiple effects on the cell cycle, SV40T alone can immortalize cells [27]. It is important to have an effective method of delivering the immortalizing genes into the target cells. The common approaches include the use of transposons or retroviral (including lentiviral) vectors to achieve efficient and stable DNA integration. We previously used the retroviral vector and piggyBac transposon-mediated expression of SV40T and immortalized several sources of progenitor cells [28-39]. However, retroviral or transposon-mediated random integration of immortalizing genes into the host genome may possess detrimental effects. Thus, safer strategies of delivering immortalizing genes should be used.

The recent discovery of CRISPR/Cas9 genome-editing system provides us an unprecedented opportunity to target and modify genomic sequences with high levels of efficacy and specificity [40-44]. CRISPR/Cas9 system induces DNA double-strand breaks at specific sites of genomic DNA, which should allow safer and targeted gene delivery of the immortalizing genes. Numerous studies have identified “safe harbor” loci in human and mouse genomes, which can be specifically targeted without causing significant detrimental effects on host genes while maintaining a high level of gene expression. Mouse Rosa26 locus is such a “safe harbor” locus for targeted integration because this site is not susceptible to gene silencing effects and provides improved targeting efficiency and ubiquitous transgene expression without alteration of the cell viability or phenotype [45, 46]. Furthermore, it is conceivable that such site-specific targeted integration of immortalization should allow more efficient removal of the immortalizing genes than that of random integrations.

In order to overcome the technical challenge of maintaining primary BMSCs in long-term culture, here we established and characterized the reversibly immortalized mouse BMSCs (imBMSCs) through the CRISPR/Cas9-mediated homology-directed-repair (HDR) mechanism. We demonstrated that mouse BMSCs were effectively immortalized by targeting SV40T into the Rosa26 locus through CRISPR/Cas9 HDR and the resultant imBMSCs retained MSC-like features both in vitro and in vivo. Furthermore, the CRISPR/Cas9 HDR-immortalized BMSCs can be reversed more effectively by the FLP recombinase than that of the BMSCs immortalized with retroviral vector-based random integrations. Therefore, the engineered imBMSCs should be a valuable resource for basic and translational research in the fields of MSC biology and regenerative medicine.

RESULTS

Mouse bone marrow stromal stem cells (mBMSCs) can be immortalized by SV40 T antigen through CRISPR/Cas9-mediated targeted integration at the Rosa26 locus

Bone marrow stromal stem cells (BMSCs) are a valuable cell type for a broad range of studies [2, 3]. While readily available, primary BMSCs are not easy to culture and grow to large quantities. Thus, there is a need to establish reversibly and/or conditionally immortalized BMSCs. While SV40 T antigen (SV40T) has been widely used to immortalize primary mammalian cells, this immortalizing gene is usually delivered by retroviral vectors or piggyBac transposon system [28, 29, 39, 47, 48], which often randomly integrate into host genome. Here, we sought to take advantage of the high genome-editing specificity feature delivered by CRISPR/Cas9 system and to target the SV40T into a safe harboring site at Rosa26 locus [49].

To accomplish the efficient expression of Cas9 and Rosa26 locus-targeting sgRNAs in target cells, we employed various cloning approaches including Gibson Assembly and constructed the pCas9gG-Rosa26 vector (Figure 1A-a). This vector contains three independent expression modules, the streptococcus pyogenes Cas9 (spCas9) expression module, the double-nicking gRNA expression modules, and the eGFP expression module which allows for monitoring of transfection efficiency. To reduce off-target effects of single gRNA-guided Cas9 nuclease, a previously reported “paired nicking” strategy was employed, in which two sgRNAs targeted to adjacent sites on opposite DNA strands [44, 50], as two sgRNA, driven by U6 promoter, were designed to target the first intron of the Rosa26 gene as reported (Figure 1A-a) [49].

For the donor template for CRISPR/Cas9-mediated homology-directed recombination, we constructed the targeting vector pRosa26-TA (Figure 1A-b), containing 692bp upstream and 636bp downstream from the cleavage site of Rosa26 locus. Between the two homology arms the vector contains the hEFH-driven SV40T-HygR bicistronic expression cassette linked by T2A self-cleaving peptide, which is flanked by FRT sites (Figure 1A-b). If the CRISPR/Cas9-mediated HDR is successful, the targeted cells should express SV40T and become resistant to hygromycin B (Figure 1A-c). Conversely, the SV40T-HygR cassette can be removed by FLP recombinase, leading to the expression of G418 resistance gene (see below).

To confirm if the above vectors could efficiently induce the integration of SV40T transgene into Rosa26 locus in mouse cells, we transfected the targeting vector pRosa26-TA and the CRISPR/Cas9-expressing vector pRosa26-Cas9gG into mouse B16F10 cells. The GFP+ cells survived hygromycin B selection (Figure 1A-d). Genomic DNA PCR analysis of the stable cell pool was carried out to examine whether the Rosa26-targeting construct successfully integrated into the target site. Using the P1 primer that recognizes a genomic sequence outside of the downstream homology arm (or right arm) of the targeting vector, together with the G418-specific primer P2, we were able to detect the expected 791bp PCR product from the hygromycin B resistant B16F10 cells (Figure 1A-e), indicating the correct integration of the target sequence at the Rosa26 locus. We further confirmed the 5´-end integrity of the targeting vector by detecting the presence of hEFH, SV40T and HygrR sequences with sequence-specific primers (Figure 1A-e). Lastly, we also used the retroviral-based immortalization vector SSR #41 as a control system in order to thoroughly compare the immortalization efficiency and FLP-mediated excision of SV40T cassette (Figure 1B). It is noteworthy that we also transfected the primary cells with single sgRNAs and found that single sgRNA seemingly exerted higher targeting efficiencies in these cells than double sgRNAs (data not shown) although thorough characterization of targeting specificity is needed.

CRISPR/Cas9 HDR-mediated SV40T targeting system efficiently immortalizes primary mouse BMSCs

We next tested if the CRISPR/Cas9 HDR-mediated SV40T targeting system can effectively immortalize mBMSCs while retaining their multipotent properties. Primary mBMSCs were readily isolated from the femur of 2-week old CD1 mice (Figure 2A-a) and effectively co-transfected with pRosa26-TA and pCas9gG-Rosa26 plasmids (Figure 2A-b). When the transfected mBMSCs were selected in hygromycin B, stable cell clones were readily formed(Figure 2A-c). The pooled stable cells were continuously passaged and designated as imBMSCs (Figure 2B-a). Similarly, using the retroviral SSR #41 vector system as previously described [28, 36, 47], we established stable and immortalized mBMSC line, designated as imBMSC41 (Figure 2B-b).

We compared the proliferative activity of the two immortalized lines with that of primary mBMSCs, and found that while the primary mBMSCs significantly proliferated over the course of 5 days the immortalized lines (especially imBMSC41) grew at much higher rates. Crystal violet staining assay indicated that both imBMSCs and imBMSC41cells reached confluence at as early as day 3, while primary BMSCs reached confluence at day 5 even though all three lines started with a similar cell density (Figure 2C-a). Quantitative assessment of the stained cells confirmed the staining results that imBMSCs and imBMSC41 cells exhibited significantly higher proliferative activity at each time points than that of primary mBMSCs (Figure 2C-b). Interestingly, imBMSC41 cells had higher proliferation rate than that of imBMSCs at day 3 (p<0.05) and day 5 (p<0.001) (Figure 2C-b), which may be indicative of higher level of SV40T expression in imBMSC41 cells. Nonetheless, these results indicate that the primary mBMSCs were stably immortalized and maintain long-term proliferation capability.

We also tested if the immortalization phenotype could be effectively reversed by FLP recombinase. Using adenovirus-mediated effective expression of FLP, we found the Ad-FLP-infected imBMSCs grew significantly slower than that of Ad-GFP-infected counterpart at each time points (Figure 2D-a). While holding a similar trend but at a much lesser extent, Ad-FLP-infected imBMSC41 cells grew slower than that of Ad-GFP-infected imBMSC41 cells (Figure 2D-a). Quantitative analysis of the stained cells indicated that FLP-mediated removal of SV40T significantly decreased cell proliferation activities of the immortalized cells (p<0.001), while Ad-FLP-infected imBMSCs exhibited more significant decreases than that of Ad-FLP-infected imBMSC41 cells at 48h, 72h and 96h (Figure 2D-b). Consistent with the above observations, the imBMSC41 exhibited much higher proliferative activity than the imBMSCs (p<0.001). Moreover, the above results indicate that FLP-mediated removal of SV40T in the imBMSCs is more efficient than that of the imBMSC41 cells.

The immortalization element in the imBMSCs can be removed by FLP recombinase more effectively than that in the imBMSC41 cells

We next analyzed the distinct features of transgene expression and FLP-mediated reversibility between the imBMSCs and imBMSC41 cells. As expected, FLP recombinase should be able to remove the SV40T and HygR, which is marked by the disappearance of the P3/P4 fragment and the presence of P5/P6 fragment in genomic PCR analysis (Figure 3A). As reported above, Ad-FLP-infected imBMSCs grew significantly slower than that of Ad-GFP-infected counterpart at each time points (Figure 2D), indicating that immortalization phenotype of both lines are reversible to various extents by FLP recombinase.

We quantitatively analyzed the effect of FLP treatment on SV40T expression in both lines. When the imBMSCs and imBMSC41 cells were infected with low and high titers of Ad-FLP or Ad-GFP for 5 days, we found that the expression level of SV40T was significantly decreased in both lines in an Ad-FLP dose-dependent fashion (Figure 3B-a). It is noteworthy that the SV40T expression level in the imBMSC41 cells was approximately 2.3-fold of that in the imBMSCs (p<0.001), which may at least partially explain the higher proliferative activity of imBMSC41 cells. However, upon Ad-FLP infection SV40T expression in imBMSCs was shown to decrease by up to 86% (higher titer), compared with 63% reduction in imBMSC41 cells at the same Ad-FLP titer (Figure 3B-b). In fact, the FLP-mediated decrease in SV40T expression in imBMSCs was more profound than that in imBMSC41 cells both at high titer (p<0.001) and low titer (p<0.05) of Ad-FLP (Figure 3B-b). Quantitative PCR analysis of genomic DNA indicates that FLP-treated imBMSCs exhibited a significant decrease in P3/P4 PCR product, along with a significant increase in P5/P6 PCR product, compared with that of the GFP-treated imBMSCs (both p<0.001) (Figure 3C). These results further confirm that the CRISPR/Cas9 HDR-targeted immortalization element can be effectively removed by FLP recombinase in the imBMSCs.

We also compared the efficiency of the FLP-mediated removal of SV40T and HygR sequences at genome level in both cell lines. Semi-quantitative PCR analysis revealed that Ad-FLP infection effectively removed SV40T sequence in imBMSCs while residual amount of SV40T sequence was still detectable (Figure 3D-a). Similarly, Ad-FLP infection was shown to remove most of the HygR sequence in imBMSCs, but to a much lesser extent in imBMSC41 cells (Figure 3D-a). Quantitative PCR analysis indicated that FLP expression effectively removed both SV40T and HygR sequences in both cell lines, compared with that of GFP-transduced cells (p<0.001) (Figure 3D-b). By comparing with the genomic level of Gapdh, we found that the average copy numbers of SV40T/HygR genes were 1.045 in imBMSCs and 2.069 in imBMSC41 cells, respectively (Figure 3D-b), indicating that a single copy of the immortalization element was integrated into the Rosa26 locus through CRISPR/Cas9 HDR system in imBMSCs, while about two copies were randomly integrated in imBMSC41 cells. At least 92% of SV40T and 82% of HygR genes could be removed by FLP recombinase in imBMSCs, compared with 58% and 54% of these genes in imBMSC41 cells, respectively (Figure 3D-c), further confirming that the FLP-mediated removal of the immortalization element in imBMSCs is much more efficient than that in imBMSC41 cells (p<0.001).

The immortalized BMSCs express most common MSC markers and retain the potential to differentiate into multiple lineages upon BMP9 stimulation

We next tested if the immortalized BMSC lines retain MSC features and functionalities. First, we examined the expression of common MSC markers in imBMSCs and imBMSC41 cells. While no single marker can be used to identify BMSC cells, several consensus MSC markers, such as CD73/NT5E, CD90/Thy-1, and CD105/Endoglin, were reported [28, 34, 35, 38, 39]. We found that the MSC markers were readily detected by immunofluorescence staining both in imBMSCs (Figure 4A top row) and imBMSC41 cells (Figure 4B top row). In addition, we found that both imBMSCs and imBMSC41 cells expressed other MSC and/or progenitor markers, including CD117/c-kit, CD29/Integrin β1 and BMPR II (Figure 4A,B, bottom row). Furthermore, the expression of hematopoietic stem cell markers CD45 and CD34 was not detected in both cell lines (data not shown). These results demonstrate that imBMSCs and imBMSC41 expressed most if not all of the common MSC markers, suggesting that these cells may retain MSC-like phenotypes.

We previously demonstrated that BMP9 is a potent inducer of osteogenic, chondrogenic, and adipogenic differentiation of MSCs [22, 24, 51], and identified several important early responsive genes induced by BMP9 in MSCs such as Smad7, Id1, Ctgf and Hey1 [52-55]. We infected imBMSCs and imBMSC41 cells with Ad-BMP9 or Ad-GFP for 36h, quantitative TqPCR analysis indicated BMP9 significantly up-regulated the expression of Smad7, Id1, Ctgf and Hey1 (p<0.001) (Figure 5A). Furthermore, BMP9 was shown to effectively induce the expression of osteogenic regulators Runx2 and osterix (Osx), chondrogenic regulator Sox9 and adipogenic regulator Pparγ2 in both lines at day 3 and/or day 7 after BMP9 stimulation (Figure 5B). In addition, two osteogenic markers osteopontin (Opn) and osteocalcin (Ocn) were significantly induced by BMP9 in imBMSCs and imBMSC41 cells (Figure 5B). Collectively, these results demonstrate that the immortalized BMSCs retain MSC features.

The immortalized BMSCs are highly responsive to BMP9-induced osteogenic signaling, which is not significantly affected by SV40 T antigen

We previously demonstrated that BMP9 is one of the most potent osteogenic factors [19, 21, 22]. Here, we analyzed if the immortalized BMSCs were responsive to BMP9 stimulation and/or the differentiation potential would be affected by FLP-mediated removal of SV40T. When imBMSCs and imBMSC41 cells were co-infected with Ad-BMP9 and Ad-FLP or Ad-GFP, we found the BMP9-induced alkaline phosphatase (ALP) activity significantly decreased in Ad-FLP transduced imBMSCs and imBMSC41 cells, compared to that of Ad-GFP-infected cells (Figure 6A-a,b). Quantitative ALP analysis also confirmed that the FLP-mediated removal of SV40T led a significant decrease in ALP activity in both imBMSCs and imBMSC41 cells at multiple time points (Figure 6B). We further determined the effect of FLP-mediated removal of SV40T on late stage osteogenic differentiation and found that FLP-mediated removal of SV40 T antigen reduced the BMP9-induced matrix mineralization in both lines, as assessed by Alizarin Red S staining, compared to that of the AdGFP-transduced cells (Figure 6C-a,b). While it remains to be further investigated why FLP-mediated removal of SV40T in both lines diminishes BMP9-induced osteogenic activity in vitro, one possible explanation is that the removal of SV40T in these cells may decrease their proliferative activity and hence significantly reduce the progenitor pools for osteogenic differentiation. Nonetheless, these results demonstrate that the immortalized BMSCs were responsive to BMP9-induced osteogenic signaling and that the expression of SV40 T antigen does not prevent the immortalized BMSCs from undergoing osteogenic lineage-specific differentiation.

Lastly, we conducted in vivo experiments to determine whether the immortalized BMSCs were tumorigenic and could fully differentiate into bone cells upon BMP9 stimulation. Using our previously established stem cell implantation assay [28, 51], we infected subconfluent imBMSCs and imBMSC41 cells with Ad-BMP9 or Ad-GFP, and injected subcutaneously into the flanks of athymic nude mice for 4 weeks. No recoverable masses were detected in both cell lines infected with Ad-GFP, suggesting that the immortalized BMSCs may be not tumorigenic or exhibit limited tumorigenic potential. However, robust bony masses were retrieved from Ad-BMP9 transduced imBMSCs and imBMSC41 cells (Figure 7A-a) although no significant differences in average bone volume and mean bone density were found between the two cell lines as determined by μCT imaging analysis (p>0.05) (Figure 7A-b,c). Accordingly, histological analysis of the retrieved masses revealed that BMP9-transduced imBMSCs and imBMSC41 cells formed robust osteoid matrix and trabecular bone, while adipocytes and to a much lesser extent, chondrocytes, were also observed within the retrieved bony masses (Figure 7B-a). It is noteworthy that significant amounts of undifferentiated BMSCs were also observed (Figure 7B-a), indicating that longer time points may be needed to allow the remaining progenitors to become fully differentiated. Trichrome staining further confirmed that BMP9 was able to induce the formation of mature bone and well-mineralized osteoid matrix (Figure 7B-b). It is noteworthy that we compared the in vitro and in vivo osteogenic activities among early passage primary BMSCs and the immortalized BMSCs lines and did not find any significant differences in their response to BMP9 stimulation (data not shown), suggesting that SV40 Tag-mediated immortalization may not significantly affect the lineage-specific differentiation potential of BMSCs. Taken together, these in vitro and in vivo results strongly suggest that both imBMSCs and imBMSC41 cells may give rise to osteogenic, chondrogenic and adipogenic lineages.

DISCUSSION

In order to accomplish the establishment of reversibly and/or conditionally immortalized BMSCs for basic and translational research, we have taken advantage of the CRISPR/Cas9-based site-specific HDR and targeted the immortalizing gene SV40T to the safe harboring site at the Rosa26 locus of mouse genome. We demonstrated that CRISPR/Cas9 HDR-mediated SV40T targeting system can efficiently immortalize primary mouse BMSCs and developed the reversibly immortalized BMSCs or imBMSCs. For a comparison, we also immortalized BMSCs with the retroviral vector SSR #41 and established the imBMSC41. Compared with primary mBMSCs, both imBMSCs and imBMSC41 exhibited long-term proliferative capability although imBMSC41 cells had significantly higher proliferation rate. Quantitative analysis indicated that imBMSC41 cells expressed approximately 130% higher level of SV40T than that of imBMSCs. High expression level of FLP recombinase led to approximately 86% reduction of SV40T expression in imBMSCs, compared with 63% in imBMSC41 cells. Quantitative genome PCR indicated that the average genomic copy number of SV40T and hygromycin was approximately 1.05 for imBMSCs and 2.07 for imBMSC41 cells, whereas genomic DNA analysis further demonstrated that FLP transduction efficiently removed the immortalization cassette from the Rosa26 locus in mBMSCs. Furthermore, FLP expression in imBMSCs was shown to remove approximately 92% of SV40T at genome DNA level, compared with 58% of that in imBMSC41 cells under the same condition. These results strongly indicate that CRISPR/Cas9-mediated immortalization of BMSCs is target site-specific and can be more effectively reversed than that of retrovirus-mediated random integration. Nonetheless, both imBMSCs and imBMSC41 cells expressed MSC markers and were highly responsive to BMP9-induced osteogenic, chondrogenic and adipogenic differentiation in vitro and in vivo. Furthermore, we demonstrated that the presence of SV40T did not prevent BMP9-induced osteogenic differentiation and that the immortalized BMSCs were non-tumorigenic in vivo.

Our results reinforce the important utility of CRISPR/Cas9-mediated site-specific genome-editing technology in biomedical research. We previously used retroviral vector and piggyBac transposon-mediated expression of SV40T to immortalize multiple progenitor cells [28-39]. While effective and successful, retroviral or transposon-mediated random integration of immortalizing genes may possess detrimental effects in host genome, and is significantly less effective to be removed by Cre or FLP recombinase. While mouse Rosa26 locus has been used as a “safe harbor” locus for targeted integration because this site is not susceptible to gene silencing effects and provides improved targeting efficiency and ubiquitous transgene expression without alteration of the cell viability or phenotype [45, 46], it is conceivable that more “safe harbor” sites can be used as CRISPR/Cas9 target sites.

Several strategies have been developed to immortalize primary cells, including somatic fusion, stable expression of viral oncogenes, hTERT and/or inactivation of tumor suppressor genes [27, 56-59]. As one of the most commonly-used immortalizing genes, SV40T exerts immortalizing properties without fully transforming the cells [60]. We previously used SV40T to immortalize various sources of progenitor cells without detecting any tumorigenic effect [28-39]. Other commonly used oncogenes include c-Myc, KRas, CDK4, Bmi-1, cyclin D1, HPV 16 E6/E7, and Telomerase (TERT) while most of them require more than one oncogene to work together to immortalize primary cells [59]. Based on our experience, SV40T is sufficient and effective to immortalize primary mouse cells, although a combination of SV40T and hTERT may be more efficient in maintaining long-term proliferation of primary human cells, especially for human progenitor cells.

Immortalized bone marrow stromal cells can be used as a promising alternative cell source of primary MSCs for basic and translational studies. One such line of investigation is to study bone morphogenetic protein (BMP)-induced osteogenic signaling and the potential use of BMPs in regenerative medicine. BMPs are considered the most potent osteoinductive factors [19, 20]. Through a comprehensive analysis of the 14 types of BMPs’ osteogenic activities, we found that BMP9 (also known as growth differentiation factor 2, or GDF2) is among the most osteogenic BMPs that induce osteoblastic differentiation of MSCs [19, 21-24]. We demonstrated that BMP9 is resistant to naturally occurring antagonist noggin, which may at least partially contribute to its potent osteogenic activity [61]. We further demonstrated that TGFβ/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in MSCs [62]. Mechanistically, BMP9 has been shown to induce osteogenic differentiation of MSCs by regulating a panel of important downstream targets [52-55, 63], as well as through cross-talk with other important signaling pathways [64-69]. Thus, using BMP9-expressing progenitor cells, such as BMSCs, may promote bone regeneration in large bony defects and/or fracture nonunion in clinical settings [23, 24, 70].

In summary, we established the reversibly immortalized imBMSCs by exploiting CRISPR/Cas9 HDR mechanism. The mBMSCs were successfully immortalized by targeting SV40T into the Rosa26 locus. The resultant imBMSCs retained MSC features both in vitro and in vivo. Furthermore, the CRISPR/Cas9 HDR-immortalized BMSCs can be reversed more effectively by the FLP recombinase, compared to BMSCs immortalized with retroviral vector-based random integrations. Moreover, we demonstrated that the presence of SV40T did not prevent BMP9-induced osteogenic differentiation and that the immortalized BMSCs were non-tumorigenic in vivo. Collectively, the engineered imBMSCs should be used as a valuable resource for basic and translational research in the fields of MSC biology and regenerative medicine.

MATERIALS AND METHODS

Cells culture, enzymes and chemicals

HEK-293 and B16F10 were obtained from ATCC (Manassas, VA). The 293pTP and RAPA cells were derived from HEK-293 cells as described [71, 72]. All cells were maintained at 37°C with 5% CO² in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS, Gemini Bio Products, West Sacramento, CA), 2mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin [73, 74]. All restriction enzymes used in cloning, the Phusion High-Fidelity PCR kit and the Gibson Assembly Master Mix were from New England Biolabs (Ipswich, MA, USA). Oligonucleotides were synthesized by IDT (Coralville, IA). Unless indicated otherwise, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or Thermo Fisher Scientific (Waltham, MA).

Construction of the pCas9gG-Rosa26 vector that expresses spCas9 and double-nicking sgRNAs targeting Rosa26 locus

As illustrated in Figure 1A-a, the pCas9gG-Rosa26 vector was constructed on the base of our homemade vector pU6CGR, which contains U6 promoter to drive small guide RNA (sgRNAs) expression. First, the CAG-spCas9 expression cassette was PCR amplified from pX330 (Addgene plasmid #42230), resulting in pCas9(CAG-spCas9-U6-EF1-eGFP-PA). Gibson Assembly reaction [75] was carried out to knockout the BmsI site in spCas9 cDNA sequence. To express dual sgRNAs that target the Rosa26 locus, we subcloned the fragments containing U6 promoter and sgRNA scaffold into the above vector. Two previously characterized Rosa26-targeting sgRNAs [49] were chosen and subcloned into the BsmI and BbsI sites, respectively: sgRNA1, GCG CAC TAG ACG TTG AGG TCagg and sgRNA2, GAA GAT GGG CGG GAG TCT TCtgg, where the PAM sequences are in lower case. Lastly, a CMV-driven eGFP expression cassette was subcloned into the vector for monitoring transfection efficiency. The final construct was designated as pCas9gG-Rosa26, which is used to deliver constitutive expression of spCas9 and a pair of gRNAs to produce dual gRNA-guided double-nicking in mouse Rosa26 locus. All cloning junctions and critical sequences were sequencing verified. Details about the vector construction are available upon request.

Construction of the donor vector pRosa26-TA that contains the Rosa26 homologous recombination arms and expresses SV40 T antigen (SV40T) and hygromycin resistance gene (HygR) flanked with FRT sites

The donor vector pRosa26-TA was constructed on the base of our homemade vector pMOK. Briefly, the 600-700bp fragments of Rosa26 left and right homologous arms were PCR amplified from mouse genomic DNA and subcloned into the EcoRI/AfeI and MluI/BspDI sites of pMOK, respectively. Gibson Assembly reactions were carried out to assemble the hEFH-driven SV40T-T2A-HygR expression cassette (Figure 1A-b). The overlapping SV40T and HygR fragments with 50bp overlapping sequences on each side, along with T2A peptide sequence preceding the HygR coding region, were PCR amplified from pMPH86 [39]. Furthermore, the SV40T-T2A-HygR cassette was flanked with FRT sites, followed by the coding region of G418 resistance gene for negative selection after FLP treatment. All cloning junctions, PCR amplified sequences, and other critical sequences were sequencing verified. Details about the vector construction are available upon request.

Isolation and culture of primary mouse bone marrow stromal stem cells (mBMSCs)

All animal studies were conducted by following the NIH guidelines approved by Institutional Animal Care and Use Committee (IACUC). Isolation and culture of primary mBMSCs from murine bone marrow were performed as previously described [76]. Briefly, 2-week old male CD1 mice (obtained from The University of Chicago Transgenic Core Facility) were euthanized. The connective tissues were removed from the femur and rinsed with sterile PBS. Both ends of the femur were cut, and the marrow plug was flushed out with syringe containing complete DMEM medium. The marrow plugs were washed in complete DMEM and plated into 100mm cell culture dishes at 37°C. After 3h incubation, the non-adherent cells were removed by replacing the medium with fresh complete medium. The medium was changed every 8h for the first 72h of culture. The cultured primary mBMSC cells were maintained in complete DMEM and used for immortalization experiments.

Establishment of reversibly immortalized mouse BMSCs (imBMSCs) using the CRISPR/Cas9-mediated SV40T expression in Rosa26 locus

Early passage BMSCs (<3 passages) were seeded in 25 cm² flasks and co-transfected with 6 μg of pRosa26-TA and 2 μg of pCas9gG-Rosa26 using 75 μg PEI (Polysciences Inc, Warrington, PA) as described [77, 78]. At 36h after transfection, cells were subjected to hygromycin B selection (at 0.1 mg/mL) for 7 days. A stable cell pool was obtained and continuously passaged for further analysis. The resultant stable line was designated as imBMSCs.

In order to compare the biological features and FLP-mediated reversibility, we also immortalized primary mBMSCs with a retroviral immortalization system described previously [28-32, 35, 36, 47]. Specifically, we infected early passage primary mBMSCs with packaged SSR #41 retroviral vector, which expresses SV40 T antigen flanked with FRT sites [47]. Experimentally, early passage mBMSCs (<3 passages) were seeded in 25 cm² flasks and infected by SSR #41 retrovirus with 3 rounds (e.g., 3-4h intervals between rounds). Stable cell pool was obtained by selecting the infected cells with hygromycin B (0.1 mg/mL) for 7 days, and was continuously passaged for further analysis. The resultant stable pool was designated as imBMSC41. Aliquots of the varied passages of imBMSCs or imBMSC41 were kept in liquid nitrogen tanks.

Generation and amplification of recombinant adenoviruses expressing BMP9, FLP recombinase and GFP

Recombinant adenoviruses were generated using the AdEasy technology as described [79, 80]. Briefly, the coding regions of human BMP9 and flippase recombinase (FLP) were PCR amplified, subcloned into an adenoviral shuttle vector, and subsequently used to generate recombinant adenoviruses in HEK-293, 293pTP or RAPA cells as described [71, 72]. The resulting adenoviruses were designated as Ad-BMP9 and Ad-FLP, both of which also express GFP as the marker for monitoring infection efficiency. An analogous adenovirus expressing only GFP (Ad-GFP) was used as mock virus control. For all adenovirus infections, polybrene (8 μg/mL) was added to the culture medium in order to enhance adenoviral transduction efficiency [81].

Total RNA isolation and touchdown quantitative real-time PCR (TqPCR)

Total RNA was isolated using TRIZOL Reagents (Invitrogen) and reverse transcribed using hexamer and M-MuLV reverse transcriptase (New England Biolabs, Ipswich, MA). The resulting cDNA products were diluted 10- to 100-fold and used as PCR templates. TqPCR was carried out by using SYBR Green-based TqPCR analysis on a CFX-Connect unit (Bio-Rad Laboratories, Hercules, CA). PCR primers were designed by using Primer3 program and were listed in Supplementary Table 1. Quantitative real-time PCR analysis was carried out by using our recently optimized TqPCR protocol [82]. Briefly, the PCR reactions were carried out by using a touchdown protocol: 95°C×3min for one cycle; 95°C×20 sec, 66°C×10 sec for 4 cycles, with 3°C decrease per cycle; followed by 95°C×10 sec, 55°C×15 sec, 70°C×1 sec for 40 cycles, followed by plate read. All reactions were done in triplicate. The TqPCR amplification was confirmed by performing the melting curve test and observing a single peak for each gene. Gapdh was used as a reference gene.

Genomic DNA characterization at the Rosa26 targeting sites

Genomic DNA was extracted from imBMSCs and imBMSC41 cells by using alkaline lysis method. The primers P1 and P2 were designed from the mouse genomic sequence immediately outside of the right homologous arm and the G418 doing sequence in the target vector (Figure 1A-c). The presence or absence of hEFH, SV40 T and hygromycin sequences was also assessed by PCR using sequence-specific primers (Supplementary Table 1). The PCR reactions were carried out by using a touchdown protocol: 95°C×3min for one cycle; 95°C×20 sec, 68°C×30 sec, 72°C×40 sec for 13 cycles, with 1°C decrease per cycle; followed by 95°C×20 sec, 55°C×30 sec, 72°C×40 sec for 20–25 cycles, depending on the transcript abundance. PCR products were confirmed on 1.2 % agarose gels.

The relative copy numbers of the transgenes were determined by TqPCR analysis. The qPCR primers were designed to detect SV40T and Hygromycin genes. TqPCR analysis was carried out as described [82]. Primers for the Gapdh promoter were used as an internal control.

Immunofluorescence staining

Immunofluorescence staining was performed as described [33, 83, 84]. Briefly, exponentially growing cells were fixed with 4% paraformaldehyde (PFA) for 10 min, washed with PBS and permeabilized with 1% NP-40 for 10min at room temperature. After being blocked with 10% donkey serum (Jackson Immuno-Research Laboratories, West Grove, PA) for 1h at room temperature, cells were incubated with various primary antibodies, including CD29, CD73, BMPRII, CD90, CD117/c-kit, CD105/endoglin, or BMPR-II antibody (all from Santa Cruz Biotechnology) for 1h at room temperature. Cells were washed with PBS and incubated with FITC-labeled secondary antibodies (Jackson ImmunoResearch Laboratories) for 30 min. DAPI (Invitrogen) was used to visualize nuclei. Stains were examined under a fluorescence microscope. Negative control cells were performed under the same conditions without primary antibodies. Representative images from at least three independent staining experiments are shown.

Early osteogenic marker alkaline phosphatase (ALP) activity assay

ALP activity was assessed quantitatively with the modified Great Escape SEAP Chemiluminescence assay kit (BD Clontech) and qualitatively with histochemical staining assay (using a mixture of 0.1 mg/ml napthol AS-MX phosphate and 0.6 mg/ml Fast Blue BB salt) as previously described [65, 68]. Each assay condition was performed in triplicate, the results were repeated at least three independent experiments and was normalized by total cellular protein concentrations among the samples.

Matrix mineralization assay (Alizarin Red staining)

The formation of mineralized matrix nodules was stained by using Alizarin Red S staining as described previously [67, 85]. Briefly, cells were co-infected with AdBMP9 and Ad-GFP or Ad-FLP, and cultured in the presence of ascorbic acid (50 μg/mL) and β-glycerophosphate (10 mM). At 10 days after infection, cells were fixed with 0.05% (v/v) glutaraldehyde at room temperature for 10 min and washed with distilled water. The fixed cells were incubated with 0.4% Alizarin Red S for 5 min, followed by extensive washing with distilled water. The staining of calcium mineral deposits was recorded under a bright field microscope. Each assay condition was done in triplicate.

Subcutaneous implantation of MSCs for ectopic bone formation

The use and care of experimental animal studies was approved by the Institutional Animal Care and Use Committee (IACUC). Stem cell-based ectopic bone formation was performed as previously described [63, 86]. Briefly, imBMSCs and imBMSC41 were infected with Ad-BMP9 or Ad-GFP for 36h, collected and resuspended in 80μL of phosphate-buffered saline (PBS) for subcutaneous injection (5×10⁶ cells/site) into the flanks of athymic nude (nu/nu) mice (5 animals per group, 4-6 weeks old, male; Harlan Laboratories, Indianapolis, IN). At 4 weeks after implantation, animals were sacrificed, and the implantation sites were retrieved for microcomputed tomography (μCT) imaging, histologic evaluation and other special staining (see below).

Micro-CT (μCT) analysis

All retrieved specimens were fixed in 10% (v/v) formalin and imaged using the μCT component of the GE triumph (GE Healthcare) trimodality preclinical imaging system. The imaging data were analyzed with Amira 5.3 software (Visage Imaging, Inc.). The 3D volumetric values and mean bone density were determined as described [87].

Histological evaluation (H&E) and trichrome staining

Retrieved tissues were fixed in 10% (v/v) formalin overnight, then decalcified and paraffin embedded. Serial sections of the embedded specimens were mounted onto slides, deparaffinized and rehydrated in a graduated fashion. H & E and Masson’s Trichrome stains were carried out as previously described [88].

Statistical analysis

All quantitative assays were performed in triplicate and/or in three independent batches. Statistical analysis was carried out using Microsoft Excel program. Data were expressed as mean ± SD. Statistical significances were determined by one-way analysis of variance and the student’s t test. A value of p<0.05 was considered statistically significant.

ACKNOWLEDGMENTS AND FUNDING

The authors thank Dr. Linda Degenstein of the Transgenic Mouse and Embryonic Stem Cell Facility at The University of Chicago for providing the animal samples. The reported work was supported in part by research grants from the National Institutes of Health (AT004418, DE020140 to TCH and RRR), the US Department of Defense (OR130096 to JMW), the Scoliosis Research Society (TCH and MJL), the National Key Research and Development Program of China (2016YFC1000803 and 2011CB707906 to TCH), the National Natural Science Foundation of China (#81401536 to WWZ), and the Foundation for Outstanding Young Scientist of Shandong Province (#BS2014YY035 to WWZ). This project was also supported in part by The University of Chicago Cancer Center Support Grant (P30CA014599) and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1 TR000430. Funding sources were not involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284:143–147.

2. Shenaq DS, Rastegar F, Petkovic D, Zhang BQ, He BC, Chen L, Zuo GW, Luo Q, Shi Q, Wagner ER, Huang E, Gao Y, Gao JL, et al. Mesenchymal progenitor cells and their orthopedic applications: forging a path towards clinical trials. Stem Cells Int. 2010; 2010:519028.

3. Rastegar F, Shenaq D, Huang J, Zhang W, Zhang BQ, He BC, Chen L, Zuo GW, Luo Q, Shi Q, Wagner ER, Huang E, Gao Y, et al. Mesenchymal stem cells: molecular characteristics and clinical applications. World J Stem Cells. 2010; 2:67–80.

4. Deng ZL, Sharff KA, Tang N, Song WX, Luo J, Luo X, Chen J, Bennett E, Reid R, Manning D, Xue A, Montag AG, Luu HH, et al. Regulation of osteogenic differentiation during skeletal development. Front Biosci. 2008; 13:2001–2021.

5. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med. 2001; 7:259–264.

6. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968; 6:230–247.

7. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966; 16:381–390.

8. Olsen BR, Reginato AM, Wang W. Bone development. Annu Rev Cell Dev Biol. 2000; 16:191–220.

9. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol. 2008; 215:442–451.

10. Kim JH, Liu X, Wang J, Chen X, Zhang H, Kim SH, Cui J, Li R, Zhang W, Kong Y, Zhang J, Shui W, Lamplot J, et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis. 2013; 5:13–31.

11. Yang K, Wang X, Zhang H, Wang Z, Nan G, Li Y, Zhang F, Mohammed MK, Haydon RC, Luu HH, Bi Y, He TC. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest. 2016; 96:116–136.

12. Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, Luu HH. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2015; 2:13–25.

13. Teven CM, Farina EM, Rivas J, Reid RR. Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis. 2014; 1:199–213.

14. Jo A, Denduluri SK, Zhang B, Wang Z, Yin L, Yan Z, Kang R, Shi LL, Mok J, Lee MJ, Haydon RC. The versatile functions of Sox9 in development, stem cells, and human diseases. Genes Dis. 2014; 1:149–161.

15. Louvi A, Artavanis-Tsakonas S. Notch and disease: a growing field. Semin Cell Dev Biol. 2012; 23:473–480.

16. Zanotti S, Canalis E. Notch and the skeleton. Mol Cell Biol. 2010; 30:886–896.

17. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet. 2012; 13:654–666.

18. Varga AC, Wrana JL. The disparate role of BMP in stem cell biology. Oncogene. 2005; 24:5713–5721.

19. Luu HH, Song WX, Luo X, Manning D, Luo J, Deng ZL, Sharff KA, Montag AG, Haydon RC, He TC. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res. 2007; 25:665–677.

20. Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S, Idowu O, Li M, Shen C, et al. Bone morphogenetic protein (BMP) signaling in development and human diseases. Genes Dis. 2014; 1:87–105.

21. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am. 2003; 85-A:1544–1552.

22. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, Deyrup AT, Jiang W, Luu HH, Luo J, Szatkowski JP, Vanichakarn P, Park JY, Li Y, et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther. 2004; 11:1312–1320.

23. Luther G, Wagner ER, Zhu G, Kang Q, Luo Q, Lamplot J, Bi Y, Luo X, Luo J, Teven C, Shi Q, Kim SH, Gao JL, et al. BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential. Curr Gene Ther. 2011; 11:229–240.

24. Lamplot JD, Qin J, Nan G, Wang J, Liu X, Yin L, Tomal J, Li R, Shui W, Zhang H, Kim SH, Zhang W, Zhang J, et al. BMP9 signaling in stem cell differentiation and osteogenesis. Am J Stem Cells. 2013; 2:1–21.

25. Phinney DG, Sensebe L. Mesenchymal stromal cells: misconceptions and evolving concepts. Cytotherapy. 2013; 15:140–145.

26. Fanning E, Knippers R. Structure and function of simian virus 40 large tumor antigen. Annu Rev Biochem. 1992; 61:55–85.

27. McLean JS. Improved techniques for immortalizing animal cells. Trends Biotechnol. 1993; 11:232–238.

28. Huang E, Bi Y, Jiang W, Luo X, Yang K, Gao JL, Gao Y, Luo Q, Shi Q, Kim SH, Liu X, Li M, Hu N, et al. Conditionally immortalized mouse embryonic fibroblasts retain proliferative activity without compromising multipotent differentiation potential. PLoS One. 2012; 7:e32428.

29. Yang K, Chen J, Jiang W, Huang E, Cui J, Kim SH, Hu N, Liu H, Zhang W, Li R, Chen X, Kong Y, Zhang J, et al. Conditional immortalization establishes a repertoire of mouse melanocyte progenitors with distinct melanogenic differentiation potential. J Invest Dermatol. 2012; 132:2479–2483.

30. Bi Y, Huang J, He Y, Zhu GH, Su Y, He BC, Luo J, Wang Y, Kang Q, Luo Q, Chen L, Zuo GW, Jiang W, et al. Wnt antagonist sfrp3 inhibits the differentiation of mouse hepatic progenitor cells. J Cell Biochem. 2009; 108:295–303.

31. Bi Y, He Y, Huang J, Su Y, Zhu GH, Wang Y, Qiao M, Zhang BQ, Zhang H, Wang Z, Liu W, Cui J, Kang Q, et al. Functional characteristics of reversibly immortalized hepatic progenitor cells derived from mouse embryonic liver. Cell Physiol Biochem. 2014; 34:1318–1338.

32. Li M, Chen Y, Bi Y, Jiang W, Luo Q, He Y, Su Y, Liu X, Cui J, Zhang W, Li R, Kong Y, Zhang J, et al. Establishment and characterization of the reversibly immortalized mouse fetal heart progenitors. Int J Med Sci. 2013; 10:1035–1046.

33. Huang J, Bi Y, Zhu GH, He Y, Su Y, He BC, Wang Y, Kang Q, Chen L, Zuo GW, Luo Q, Shi Q, Zhang BQ, et al. Retinoic acid signalling induces the differentiation of mouse fetal liver-derived hepatic progenitor cells. Liver Int. 2009; 29:1569–1581.

34. Lu S, Wang J, Ye J, Zou Y, Zhu Y, Wei Q, Wang X, Tang S, Liu H, Fan J, Zhang F, Farina EM, Mohammed MM, et al. Bone morphogenetic protein 9 (BMP9) induces effective bone formation from reversibly immortalized multipotent adipose-derived (iMAD) mesenchymal stem cells. Am J Transl Res. 2016; 8:3710–3730.

35. Wang J, Zhang H, Zhang W, Huang E, Wang N, Wu N, Wen S, Chen X, Liao Z, Deng F, Yin L, Zhang J, Zhang Q, et al. Bone morphogenetic protein-9 (BMP9) effectively induces osteo/odontoblastic differentiation of the reversibly immortalized stem cells of dental apical papilla. Stem Cells Dev. 2014; 23:1405–1416.

36. Lamplot JD, Liu B, Yin L, Zhang W, Wang Z, Luther G, Wagner E, Li R, Nan G, Shui W, Yan Z, Rames R, Deng F, et al. Reversibly immortalized mouse articular chondrocytes acquire long-term proliferative capability while retaining chondrogenic phenotype. Cell Transplant. 2015; 24:1053–1066.

37. Denduluri SK, Scott B, Lamplot JD, Yin L, Yan Z, Wang Z, Ye J, Wang J, Wei Q, Mohammed MK, Haydon RC, Kang RW, He TC, et al. Immortalized mouse achilles tenocytes demonstrate long-term proliferative capacity while retaining tenogenic properties. Tissue Eng Part C Methods. 2016; 22:280–289.

38. Song D, Zhang F, Reid RR, Ye J, Wei Q, Liao J, Zou Y, Fan J, Ma C, Hu X, Qu X, Chen L, Li L, et al. BMP9 induces osteogenesis and adipogenesis in the immortalized human cranial suture progenitors from the patent sutures of craniosynostosis patients. J Cell Mol Med. 2017; 21:2782-2795.

39. Wang N, Zhang W, Cui J, Zhang H, Chen X, Li R, Wu N, Chen X, Wen S, Zhang J, Yin L, Deng F, Liao Z, et al. The piggybac transposon-mediated expression of SV40 t antigen efficiently immortalizes mouse embryonic fibroblasts (MEFs). PLoS One. 2014; 9:e97316.

40. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013; 10:957–963.

41. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346:1258096.

42. Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. 2015; 15:387–395.

43. Wang H, La Russa M, Qi LS. CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem. 2016; 85:227–264.

44. Zhang H, Yan Z, Li M, Peabody M, He TC. CRISPR clear? dimeric Cas9-FoK1 nucleases improve genome-editing specificity. Genes Dis. 2014; 1:6–7.

45. Zambrowicz BP, Imamoto A, Fiering S, Herzenberg LA, Kerr WG, Soriano P. Disruption of overlapping transcripts in the rosa beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci U S A. 1997; 94:3789–3794.

46. Soriano P. Generalized lacz expression with the ROSA26 cre reporter strain. Nat Genet. 1999; 21:70–71.

47. Westerman KA, Leboulch P. Reversible immortalization of mammalian cells mediated by retroviral transfer and site-specific recombination. Proc Natl Acad Sci U S A. 1996; 93:8971–8976.

48. Chen X, Cui J, Yan Z, Zhang H, Chen X, Wang N, Shah P, Deng F, Zhao C, Geng N, Li M, Denduluri SK, Haydon RC, et al. Sustained high level transgene expression in mammalian cells mediated by the optimized piggybac transposon system. Genes Dis. 2015; 2:96–105.

49. Sato T, Sakuma T, Yokonishi T, Katagiri K, Kamimura S, Ogonuki N, Ogura A, Yamamoto T, Ogawa T. Genome editing in mouse spermatogonial stem cell lines using TALEN and double-nicking CRISPR/Cas9. Stem Cell Reports. 2015; 5:75–82.

50. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, Church GM. Cas9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31:833–838.

51. Kang Q, Song WX, Luo Q, Tang N, Luo J, Luo X, Chen J, Bi Y, He BC, Park JK, Jiang W, Tang Y, Huang J, et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev. 2009; 18:545–559.

52. Peng Y, Kang Q, Cheng H, Li X, Sun MH, Jiang W, Luu HH, Park JY, Haydon RC, He TC. Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. J Cell Biochem. 2003; 90:1149–1165.

53. Peng Y, Kang Q, Luo Q, Jiang W, Si W, Liu BA, Luu HH, Park JK, Li X, Luo J, Montag AG, Haydon RC, He TC. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem. 2004; 279:32941–32949.

54. Luo Q, Kang Q, Si W, Jiang W, Park JK, Peng Y, Li X, Luu HH, Luo J, Montag AG, Haydon RC, He TC. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem. 2004; 279:55958–55968.

55. Sharff KA, Song WX, Luo X, Tang N, Luo J, Chen J, Bi Y, He BC, Huang J, Li X, Jiang W, Zhu GH, Su Y, et al. Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem. 2009; 284:649–659.

56. MacDonald C. Development of new cell lines for animal cell biotechnology. Crit Rev Biotechnol. 1990; 10:155–178.

57. Shay JW, Wright WE, Werbin H. Defining the molecular mechanisms of human cell immortalization. Biochim Biophys Acta. 1991; 1072:1–7.

58. Reddel RR. The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 2000; 21:477–484.

59. Ramboer E, De Craene B, De Kock J, Vanhaecke T, Berx G, Rogiers V, Vinken M. Strategies for immortalization of primary hepatocytes. J Hepatol. 2014; 61:925–943.

60. Fanning E. Simian virus 40 large T antigen: the puzzle, the pieces, and the emerging picture. J Virol. 1992; 66:1289–1293.

61. Wang Y, Hong S, Li M, Zhang J, Bi Y, He Y, Liu X, Nan G, Su Y, Zhu G, Li R, Zhang W, Wang J, et al. Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells. J Orthop Res. 2013; 31:1796–1803.

62. Luo J, Tang M, Huang J, He BC, Gao JL, Chen L, Zuo GW, Zhang W, Luo Q, Shi Q, Zhang BQ, Bi Y, Luo X, et al. TGFbeta/BMP type i receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem. 2010; 285:29588–29598.

63. Huang E, Zhu G, Jiang W, Yang K, Gao Y, Luo Q, Gao JL, Kim SH, Liu X, Li M, Shi Q, Hu N, Wang L, et al. Growth hormone synergizes with BMP9 in osteogenic differentiation by activating the JAK/STAT/IGF1 pathway in murine multilineage cells. J Bone Miner Res. 2012; 27:1566–1575.

64. Tang N, Song WX, Luo J, Luo X, Chen J, Sharff KA, Bi Y, He BC, Huang JY, Zhu GH, Su YX, Jiang W, Tang M, et al. BMP9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signaling. J Cell Mol Med. 2009; 13:2448–2464.

65. Chen L, Jiang W, Huang J, He BC, Zuo GW, Zhang W, Luo Q, Shi Q, Zhang BQ, Wagner ER, Luo J, Tang M, Wietholt C, et al. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res. 2010; 25:2447–2459.

66. Zhang W, Deng ZL, Chen L, Zuo GW, Luo Q, Shi Q, Zhang BQ, Wagner ER, Rastegar F, Kim SH, Jiang W, Shen J, Huang E, et al. Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. PLoS One. 2010; 5:e11917.

67. Hu N, Jiang D, Huang E, Liu X, Li R, Liang X, Kim SH, Chen X, Gao JL, Zhang H, Zhang W, Kong YH, Zhang J, et al. BMP9-regulated angiogenic signaling plays an important role in the osteogenic differentiation of mesenchymal progenitor cells. J Cell Sci. 2013; 126:532–541.

68. Liu X, Qin J, Luo Q, Bi Y, Zhu G, Jiang W, Kim SH, Li M, Su Y, Nan G, Cui J, Zhang W, Li R, et al. Cross-talk between egf and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells. J Cell Mol Med. 2013; 17:1160–1172.

69. Zhang H, Wang J, Deng F, Huang E, Yan Z, Wang Z, Deng Y, Zhang Q, Zhang Z, Ye J, Qiao M, Li R, Wang J, et al. Canonical Wnt signaling acts synergistically on BMP9-induced osteo/odontoblastic differentiation of stem cells of dental apical papilla (SCAPs). Biomaterials. 2015; 39:145–154.

70. Luo J, Sun MH, Kang Q, Peng Y, Jiang W, Luu HH, Luo Q, Park JY, Li Y, Haydon RC, He TC. Gene therapy for bone regeneration. Curr Gene Ther. 2005; 5:167–179.

71. Wu N, Zhang H, Deng F, Li R, Zhang W, Chen X, Wen S, Wang N, Zhang J, Yin L, Liao Z, Zhang Z, Zhang Q, et al. Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in hek-293 packaging cells. Gene Ther. 2014; 21:629–637.

72. Wei Q, Fan J, Liao J, Zou Y, Song D, Liu J, Cui J, Liu F, Ma C, Hu X, Li L, Yu Y, Qu X, et al. Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses. Cell Physiol Biochem. 2017; 41:2383–2398.

73. Liao J, Wei Q, Fan J, Zou Y, Song D, Liu J, Liu F, Ma C, Hu X, Li L, Yu Y, Qu X, Chen L, et al. Characterization of retroviral infectivity and superinfection resistance during retrovirus-mediated transduction of mammalian cells. Gene Ther. 2017; 24:333–341.

74. Fan J, Wei Q, Liao J, Zou Y, Song D, Xiong D, Ma C, Hu X, Qu X, Chen L, Li L, Yu Y, Yu X, et al. Noncanonical Wnt signaling plays an important role in modulating canonical Wnt-regulated stemness, proliferation and terminal differentiation of hepatic progenitors. Oncotarget. 2017; 8:27105–27119. https://doi.org/10.18632/oncotarget.15637.

75. Deng F, Chen X, Liao Z, Yan Z, Wang Z, Deng Y, Zhang Q, Zhang Z, Ye J, Qiao M, Li R, Denduluri S, Wang J, et al. A simplified and versatile system for the simultaneous expression of multiple sirnas in mammalian cells using gibson DNA assembly. PLoS One. 2014; 9:e113064.

76. Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc. 2009; 4:102–106.

77. Zhang F, Li Y, Zhang H, Huang E, Gao L, Luo W, Wei Q, Fan J, Song D, Liao J, Zou Y, Liu F, Liu J, et al. Anthelmintic mebendazole enhances cisplatin’s effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC). Oncotarget. 2017; 8:12968–12982. https://doi.org/10.18632/oncotarget.14673.

78. Deng Y, Wang Z, Zhang F, Qiao M, Yan Z, Wei Q, Wang J, Liu H, Fan J, Zou Y, Liao J, Hu X, Chen L, et al. A blockade of IGF signaling sensitizes human ovarian cancer cells to the anthelmintic niclosamide-induced anti-proliferative and anticancer activities. Cell Physiol Biochem. 2016; 39:871–888.

79. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95:2509–2514.

80. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, Vogelstein B, He TC. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007; 2:1236–1247.

81. Zhao C, Wu N, Deng F, Zhang H, Wang N, Zhang W, Chen X, Wen S, Zhang J, Yin L, Liao Z, Zhang Z, Zhang Q, et al. Adenovirus-mediated gene transfer in mesenchymal stem cells can be significantly enhanced by the cationic polymer polybrene. PLoS One. 2014; 9:e92908.

82. Zhang Q, Wang J, Deng F, Yan Z, Xia Y, Wang Z, Ye J, Deng Y, Zhang Z, Qiao M, Li R, Denduluri SK, Wei Q, et al. TqPCR: a touchdown qPCR assay with significantly improved detection sensitivity and amplification efficiency of sybr green qPCR. PLoS One. 2015; 10:e0132666.

83. Zhu GH, Huang J, Bi Y, Su Y, Tang Y, He BC, He Y, Luo J, Wang Y, Chen L, Zuo GW, Jiang W, Luo Q, et al. Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cells. Differentiation. 2009; 78:195–204.

84. Li R, Zhang W, Cui J, Shui W, Yin L, Wang Y, Zhang H, Wang N, Wu N, Nan G, Chen X, Wen S, Deng F, et al. Targeting BMP9-promoted human osteosarcoma growth by inactivation of notch signaling. Curr Cancer Drug Targets. 2014; 14:274–285.

85. Liao J, Yu X, Hu X, Fan J, Wang J, Zhang Z, Zhao C, Zeng Z, Shu Y, Zhang R, Yan S, Li Y, Zhang W, et al. lncRNA H19 mediates BMP9-induced osteogenic differentiation of mesenchymal stem cells (MSCs) through notch signaling. Oncotarget. 2017; 8:53851-53601. https://doi.org/10.18632/oncotarget.18655.

86. Wang J, Liao J, Zhang F, Song D, Lu M, Liu J, Wei Q, Tang S, Liu H, Fan J, Zou Y, Guo D, Huang J, et al. NEL-like molecule-1 (Nell1) is regulated by bone morphogenetic protein 9 (BMP9) and potentiates BMP9-induced osteogenic differentiation at the expense of adipogenesis in mesenchymal stem cells. Cell Physiol Biochem. 2017; 41:484–500.

87. Liao J, Wei Q, Zou Y, Fan J, Song D, Cui J, Zhang W, Zhu Y, Ma C, Hu X, Qu X, Chen L, Yu X, et al. Notch signaling augments BMP9-induced bone formation by promoting the osteogenesis-angiogenesis coupling process in mesenchymal stem cells (MSCs). Cell Physiol Biochem. 2017; 41:1905–1923.

88. Ye J, Wang J, Zhu Y, Wei Q, Wang X, Yang J, Tang S, Liu H, Fan J, Zhang F, Farina EM, Mohammed MK, Zou Y, et al. A thermoresponsive polydiolcitrate-gelatin scaffold and delivery system mediates effective bone formation from BMP9-transduced mesenchymal stem cells. Biomed Mater. 2016; 11:025021.